Atlas Trials

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Clinical trial NCT06557330 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06557330
Sponsor
Fox Chase Cancer Center
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
LymphomaIndolent Non-hodgkin Lymphoma
Start date
2025-06-01
Primary completion
2027-09-29
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.